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Introduction: key differences between
2002 and 2007 guidelines
In 2007, the American College of Cardiology⁄American
Heart Association (ACC⁄AHA) published new guide-
lines for the diagnosis and management of patients
with unstable angina⁄non-ST-elevation myocardial
infarction (UA⁄NSTEMI) (1). The major revisions in
the 2007 guidelines (1) since the 2002 guidelines
reﬂect the growing interest and research into
improving outcomes in patients with acute coronary
syndromes (ACS) (2). On patient presentation, it is
important to diagnose correctly and risk-stratify
according to the guidelines. Some novel biomarkers,
e.g. B-type natriuretic peptide (BNP), and risk-
assessment models such as the Thrombolysis In
Myocardial Infarction (TIMI) score, the Global Reg-
istry of Acute Coronary Events (GRACE) or the
Platelet Glycoprotein (GP) IIb⁄IIIa in Unstable
Angina: Receptor Suppression Using Integrilin Ther-
apy (PURSUIT) scores may be useful additions to
help physicians correctly risk-stratify their patients.
Secondly, the guidelines seem to encourage the use
of invasive management, rather than ischaemia-
guided management, although there is increasing evi-
dence to encourage appropriate risk stratiﬁcation
before deciding whether patients need to be managed
according to a conservative or invasive strategy.
There are also new recommendations regarding the
use of clopidogrel or GP IIb⁄IIIa inhibitors, which
are incorporated in the 2007 guidelines. Further-
more, the Organisation to Assess Strategies in Acute
Ischemic Syndrome (OASIS)-5 (3) and Acute Cathe-
terisation and Urgent Intervention Triage StrategY
(ACUITY) (4) trials provide new information regard-
ing the use of fondaparinux and bivalirudin respec-
tively in the management of patients with NSTEMI.
This review not only critically evaluates new data
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SUMMARY
Background: In 2007, the American College of Cardiology⁄American Heart Asso-
ciation (ACC⁄AHA) published new guidelines for the diagnosis and management of
patients with unstable angina⁄non-ST segment elevation myocardial infarction
(UA⁄NSTEMI). These guidelines include some important updates on the use of
clopidogrel, fondaparinux, bivalirudin and low-molecular-weight heparins (LMWHs)
all of which have published landmark clinical trials in patients with acute coronary
syndromes (ACS) since the publication of the 2002 guidelines. While these 2007
guidelines are more comprehensive and up-to-date compared with the recommen-
dations published in 2002, they also raise many questions for practising emergency
physicians and cardiologists. Methods: This article presents a critical review of
the 2007 ACC⁄AHA UA⁄NSTEMI guidelines, highlighting some of the areas of
controversy, with the aim of providing some further guidance to practising physi-
cians. Conclusions: Despite recent updates to the ACC⁄AHA UA⁄NSTEMI guide-
lines, additional factors need to be taken into consideration in the management of
UA⁄NSTEMI patients. Integrating initial responses with early or selectively invasive
strategies and the risks of complications in subsequent procedures require careful
consideration. Protocol development within an institution is required to risk-stratify
patients rapidly, provide optimum precatheterisation medical management and
allow seamless and rapid transitions to the catheterisation laboratory in patients
at risk for adverse events.
Review Criteria
• This article presents a critical review of the 2007
ACC ⁄AHA UA ⁄ NSTEMI guideline updates.
• MEDLINE was searched in September 2007 to
identify relevant clinical trials, abstracts, case
reports and articles using search terms
appropriate to areas of interest identiﬁed by the
authors. The reference lists of pertinent articles
were reviewed to identify additional publications.
Message for the Clinic
• Despite recent updates to the ACC ⁄ AHA
guidelines for the diagnosis and management of
patients with UA ⁄NSTEMI, there are gaps in the
knowledge base.
• Decisions regarding adopting an early vs. a
selectively invasive strategy should only be
considered after a thorough risk assessment has
been performed.
• Protocol development within an institution should
facilitate optimum precatheterisation medical
management and allow seamless and rapid
transitions to the catheterisation laboratory.
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evidence and remaining controversies in the manage-
ment of patients with NSTEMI (1).
Risk stratiﬁcation: markers and tools
The 2007 ACC⁄AHA guideline recommendations for
early risk stratiﬁcation (1) remain essentially
unchanged since publication of the 2002 guidelines
(2). They state that patients should be stratiﬁed into
one of three groups: low-, moderate- and high-risk,
according to their risk factors. These risk factors
include anginal symptoms, physical ﬁndings, electro-
cardiogram (ECG) ﬁndings and cardiac biomarkers.
An early ECG, within 10 min of arrival in the emer-
gency department, receives a class I recommendation
(level of evidence: B). Previously, troponin was rec-
ommended as a very good predictor of risk (2) and
the updated guidelines also mention the use of BNP
as a potentially useful biomarkers for risk assessment
(class IIb recommendation; level of evidence: B) (1).
The TIMI or GRACE risk scores or PURSUIT risk
model are recommended as useful for assisting deci-
sion-making with regard to treatment options in
patients with suspected ACS (class IIa recommenda-
tion; level of evidence: B) (1). In addition, the
elevated risk of bleeding and adverse events is high-
lighted for patients with advanced age, female sex
and chronic renal insufﬁciency. However, the new
guideline recommendations do not discuss the treat-
ment pathways according to the patients’ risk scores
(low-, moderate- and high-risk), but instead, refer to
treatment decisions in the context of whether conser-
vative or invasive management strategies are to be
employed. This represents a departure from the 2002
guidelines (2) and makes upstream (i.e. before diag-
nostic angiography) drug treatment decisions difﬁ-
cult, especially when the downstream management
strategy is unknown.
Practical usage of risk-stratiﬁcation tools
The three risk-stratiﬁcation tools have a number of
factors in common, particularly advanced age, ST-
segment deviation and elevated cardiac markers.
However, they are different in terms of other param-
eters, their practical application and which outcomes
they predict. The GRACE risk model is unsuitable
for risk stratiﬁcation of patients for initial treatment,
but can calculate the probability of in-hospital mor-
tality (5) or 6-month postdischarge mortality (6),
while the PURSUIT model predicts the rate of 30-
day mortality and the composite end-point of death
or myocardial (re)infarction (7). The PURSUIT and
GRACE risk scores involve a complex calculation of
risk, as they include both dichotomous and continu-
ous variables, and require the use of computer-based
programs based on published nomograms. A free
version of the GRACE risk-assessment tool can be
found online (http://www.outcomes-umassmed.org/
grace/acs_risk.cfm). The TIMI risk score appears to
be the simplest to remember and apply in general
clinical practice. Patients are assigned a value of 1
for each prognostic variable and the patients’ total
score determines their risk stratum, which is used to
predict clinical outcomes and provide a basis for
making treatment decisions (8) The TIMI-11B study
demonstrated that the rate of all-cause mortality,
myocardial infarction (MI) or severe recurrent
ischaemia increased signiﬁcantly as the TIMI risk
score increased (p < 0.001) (8).
Our approach
At the Wake Forest University Health Science
Department of Emergency Medicine, we use a com-
bination of markers, ECG ﬁndings and risk scores to
determine initial treatment and disposition. Patients
with new ST depression, transient elevation or an
elevated troponin are automatically considered high
risk and treated via an invasive pathway according to
the new guidelines. In the absence of ECG or marker
changes, we use an adapted TIMI score to stratify
patients into high-risk (TIMI score ‡ 4), intermedi-
ate-risk (TIMI score 2–3) or low-risk (TIMI score
0–1) ACS. Each of these groups is placed in distinct
risk-matched treatment pathways with certain phar-
macotherapies and diagnostic or management strate-
gies that are predetermined and correspond to the
new guideline recommendations (Figure 1).
Risk stratiﬁcation: invasive vs.
conservative management
An early invasive strategy (e.g. diagnostic angiogra-
phy with intent to perform revascularisation) is indi-
cated in UA⁄NSTEMI patients (without serious
comorbidities or contraindications to such proce-
dures) who have: either refractory angina or haemo-
dynamic or electrical instability (level of evidence: B)
or an elevated risk for clinical events as outlined in
Table 1 (level of evidence: A). A conservative (e.g.
selectively invasive) strategy may be considered in
initially stabilised patients (without serious comor-
bidities or contraindications to such procedures)
who have an elevated risk for clinical events (as
outlined in Table 1), including those who are tropo-
nin-positive, although this is a very weak recommen-
dation (class IIb recommendation; level of evidence:
B) (1).
The recommendations for this predominantly
invasive approach are primarily based on three large
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(FRISC)-II trial (9), the Treat Angina with Aggrastat
and Determine Cost of Therapy with an Invasive or
Conservative Strategy–Thrombolysis in Myocardial
Infarction 18 (TACTICS–TIMI-18) trial (10) and
the third Randomised Intervention Treatment of
Angina (RITA 3) trial (11). These studies showed
that an early invasive strategy was beneﬁcial for pre-
venting ischaemic outcomes, especially in subgroups
of patients at high risk, such as those presenting
with an elevated cardiac troponin level. For exam-
ple, one study showed that the odds ratio (OR) for
death, non-fatal MI or re-hospitalisation was 0.44
[95% conﬁdence interval (CI) 0.30–0.66] at 30 days
and 0.55 (95% CI 0.40–0.75) at 6 months in
patients with elevated troponin levels (10). These
ﬁndings were conﬁrmed in a meta-analysis of trials
comparing a routine invasive strategy with a more
conservative strategy in patients with NSTEMI. This
meta-analysis showed that routine invasive strategies
were more effective in preventing MI (7.3% vs.
Figure 1 Risk-stratiﬁcation ﬂow diagram for non-ST-elevation myocardial infarction (NSTEMI) acute coronary syndrome
(ACS) patients, from the Wake Forest University Health Science, Department of Emergency Medicine
Table 1 Selection of initial treatment strategy: invasive vs. conservative strategy
Preferred strategy Patient characteristics
Invasive Recurrent angina or ischaemia at rest or with low-level activities despite intensive medical therapy
Elevated cardiac biomarkers (troponin I or T)
New or presumably new ST-segment depression
Signs or symptoms of heart failure or new or worsening mitral regurgitation
High-risk ﬁndings from non-invasive testing
Haemodynamic instability
Sustained ventricular tachycardia
PCI within 6 months
Prior CABG
High-risk score (e.g. TIMI, GRACE)
Reduced left-ventricular function (LVEF < 40%)
Conservative Low-risk score (e.g. TIMI, GRACE)
Patient or physician preference in the absence of high-risk features
CABG, coronary artery bypass graft surgery; GRACE, Global Registry of Acute Coronary Events; LVEF, left-ventricular ejection fraction;
PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
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(11.2% vs. 14.0%, OR 0.77, 95% CI 0.68–0.87) and
re-hospitalisation (32.5% vs. 41.3%, OR 0.66, 95%
CI 0.60–0.72) when compared with a conservative
strategy (12).
Historically, an ischaemia-guided approach was
adopted in patients presenting with suspected cases
of UA⁄MI. In this strategy, patients only receive
diagnostic cardiac catheterisation and revascularisa-
tion if myocardial ischaemia has been objectively
diagnosed, such as through recurrent symptoms or
provocative stress testing. However, as early trial
data increasingly supported better outcomes with an
‘early invasive’ strategy (9–11), there has been a
decline in ischaemia-guided medical management.
Accordingly, patients presenting with elevated risk
for adverse outcomes from ACS are now routinely
referred for early coronary angiography and increas-
ingly undergo percutaneous coronary intervention
(PCI).
However, not all studies support an early invasive
strategy for all patients. For example, the Invasive vs.
Conservative Treatment in Unstable Coronary Syn-
dromes (ICTUS) trial compared an early invasive to
a selectively invasive strategy using low-molecular-
weight heparin (LMWH), GP IIb⁄IIIa inhibition
(clopidogrel) and intensive lipid-lowering therapy in
high-risk UA⁄NSTEMI patients (with elevated cardiac
troponin T levels) (13). The selectively invasive strat-
egy was associated with similar outcomes compared
with early invasive strategy, across a spectrum of
high-risk patients (Figure 2) (13). These outcomes
were consistently observed in both the short- (13) and
long-term (14). It should be noted that the medical
management in ICTUS was very aggressive and that a
high percentage of patients in the ‘conservative’ arm
underwent early revascularisation.
Furthermore, there is conﬂicting evidence from
the FRISC-II and RITA 3 trials regarding the long-
term beneﬁts of an early invasive strategy (15–17).
Variable 
Overall  1200 (100) 
671 (56) 
529 (44) 
880 (73) 
320 (27) 
166 (14) 
1034 (86) 
574 (50) 
575 (50) 
588 (49) 
612 (51) 
0.0 0.5  1.5  1.0 2.0 
22.7 
22.0 
23.6 
21.5 
26.1 
31.4 
21.3 
26.8 
18.4 
21.9 
23.5 
21.2 
Early 
invasive 
strategy 
Selectively 
invasive 
strategy 
18.5 
24.4 
19.6 
25.3 
28.8 
20.0 
23.5 
18.5 
18.6 
23.6 
Age < 65 yr
Male sex 
Female sex 
Diabetes 
No diabetes 
ST-segment deviation ≥ 0.1 mV
Cardiac troponin T level ≥ 0.3 µg/liter
Cardiac troponin T level < 0.3 µg/liter
ST-segment deviation < 0.1 mV
Age ≥ 65 yr
No. (%)  Relative Risk 
Rate of Primary 
End Point (%) 
Early Invasive 
Strategy Better 
Selectively Invasive 
Strategy Better 
Figure 2 Comparison of primary outcome (composite of death, non-fatal myocardial infarction, or re-hospitalisation for anginal symptoms within
1 year) with an early invasive vs. a selectively invasive strategy in acute coronary syndromes (ACS) (reproduced with permission from de Winter,
et al.; Invasive vs. Conservative Treatment in Unstable Coronary Syndromes (ICTUS) Investigators. Early invasive vs. selectively invasive management
for acute coronary syndromes. N Engl J Med 2005; 353: 1095–1104) (13). ª 2005 Massachusetts Medical Society. All rights reserved
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ment was associated with a signiﬁcant reduction in
mortality at 2 years [3.7% vs. 5.4%, relative risk
(RR) 0.68, 95% CI 0.47–0.98, p = 0.04] (15), but
that this beneﬁt was not sustained at 5 years (9.7%
vs. 10.1%, RR 0.95, 95% CI 0.75–1.21, p = 0.69)
(16). In the RITA 3 study, the survival curves started
to diverge in favour of the early invasive strategy
only after 2 years, resulting in a mortality of 12.1%
with the early invasive strategy and 15.1% with the
conservative strategy at 5 years (OR 0.76, 95% CI
0.58–1.00, p = 0.054) (17).
Further consideration needs to be given to the
patient groups for whom the intensive nature of an
invasive upstream treatment strategy may not be
appropriate, e.g. in women with low-risk features,
the extremely elderly, patients presenting with severe
renal dysfunction and those patients who have
previously undergone coronary bypass surgery or
PCI (1).
Studies have shown that event rates increase signif-
icantly with each additional risk factor (p < 0.001 for
trend) (8) and that the greatest clinical beneﬁts are
seen when patients are managed according to their
individual risk (8,10,18). Patients who receive the
most beneﬁt from the early invasive approach appear
to be those with elevated troponin levels and⁄or
TIMI risk scores of ‡ 4. Collectively, these data sug-
gest that efforts should focus on providing invasive
strategies to patients who would beneﬁt most from
these interventions and therefore, risk stratiﬁcation
of patients with UA⁄NSTEMI is very important
before deciding on a future management approach.
Use of GP IIb⁄IIIa inhibitors and⁄or
clopidogrel
According to the ACC⁄AHA guidelines (1), antiplat-
elet therapy in addition to aspirin should be initiated
before diagnostic angiography (upstream), with
either clopidogrel (loading dose followed by daily
maintenance dose) or an intravenous (i.v.) GP
IIb⁄IIIa inhibitor (class I recommendation; level of
evidence: A) (1). Clopidogrel can also be used in
conjunction with i.v. GP IIb⁄IIIa inhibitor (class IIa
recommendation; level of evidence: B). Factors
favouring administration of both agents include:
delay to angiography, high-risk features such as ele-
vated troponin and early recurrent ischaemic dis-
comfort. These two recommendations imply that the
treatment approach may vary according to the
patient’s characteristics.
There is good evidence that treatment with clopi-
dogrel prior to PCI prevents postprocedural ischae-
mic complications (19,20). The First Intracoronary
Stenting and Antithrombotic Regimen: Rapid Early
Action for Coronary Treatment (ISAR-REACT) trial
investigated the use of a 600 mg loading dose of
clopidogrel with or without GP IIb⁄IIIa inhibitors in
low-risk patients undergoing PCI (21). Clopidogrel
alone was well tolerated and associated with a low
frequency of early complications, but there was no
additional clinically measurable beneﬁt at 30 days
with the administration of the GP IIb⁄IIIa inhibitor,
abciximab, in this low-risk cohort (21).
Other studies have shown that the most beneﬁt
from GP IIb⁄IIIa inhibitors is observed in patients at
intermediate-to-high risk requiring PCI (22–27). For
example, among high-risk patients with an elevated
troponin level, the ISAR-REACT 2 study found that
the incidence of events was signiﬁcantly lower with
concurrently administered clopidogrel and abciximab
(67⁄513 patients; 13.1%) than clopidogrel and pla-
cebo (98⁄536 patients; 18.3%). This corresponded to
an RR of 0.71 (95% CI 0.54–0.95, p = 0.02)
(p = 0.07 for the interaction) (28). These results sup-
port the utilisation of clopidogrel and GP IIb⁄IIIa
inhibitors in high-risk NSTEMI ACS patients, espe-
cially those with elevated troponin levels.
However, the beneﬁts of these treatments in certain
subgroups of patients, such as the elderly and patients
with renal impairment, are less certain. For instance,
reports on the efﬁcacy of GP IIb⁄IIIa inhibitors in the
elderly show apparently contradictory results (29–31).
One study reported a reduction in major ischaemic
events associated with GP IIb⁄IIIa inhibitors in
elderly patients (10% vs. 5.9%, OR 0.56, 95% CI
0.30–0.83) (29), whereas the other showed no signiﬁ-
cant differences (9.9% vs. 10.9%, RR 1.10, 95% CI
0.72–1.69, p = 0.65) (30). Furthermore, the suitability
of using concomitant GP IIb⁄IIIa inhibitors and clop-
idogrel in these potentially high-risk patient sub-
groups is yet to be established.
In summary, the ﬁndings from these trials reinforce
the need for careful evaluation of risks, clinical features
and patient characteristics most associated with bene-
ﬁts when selecting therapeutic regimens (32). Risk
stratiﬁcation should enable physicians to select which
patients should receive clopidogrel alone or clopido-
grel in combination with GP IIb⁄IIIa inhibitors.
Pretreatment with clopidogrel prior
to invasive procedures
Clopidogrel is recommended by the ACC⁄AHA
guidelines either during an invasive or conservative
approach (class IA recommendation; level of evi-
dence: A) (1). In the PCI Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE) study,
the frequency of death or MI in the 30 days after
646 ACC⁄AHA guidelines for UA⁄NSTEMI
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been pretreated with clopidogrel for a median of
10 days compared with those patients who received
no pretreatment (4.4% vs. 2.8%, relative risk reduc-
tion 34%, p < 0.04) (33). There was no signiﬁcant
increase in major or minor bleeding associated with
clopidogrel pretreatment in patients who underwent
a percutaneous revascularisation (33). On the basis
of this study, it seems that early treatment with clop-
idogrel reduces early ischaemic events.
However, the use of clopidogrel may not be
appropriate for all patients. Between 12% and 27%
of patients requiring coronary revascularisation
undergo coronary artery bypass grafting (CABG) as
their primary mode of therapy (9,10,34,35). Some
studies suggest that the use of clopidogrel pretreat-
ment may increase the risk of 30-day any major
bleeding when compared with no pretreatment
(2.0% vs. 1.5%, RR 1.31, 95% CI 1.01–1.70) (36). As
bleeding represents a serious complication for CABG,
early risk stratiﬁcation is key to the identiﬁcation of
those who may need urgent CABG and who should
not receive clopidogrel. This risk-stratiﬁcation strat-
egy will minimise the bleeding risk for those pro-
ceeding to CABG, while ensuring that patients
undergoing PCI beneﬁt from clopidogrel treatment
(37).
Use of antithrombins in the invasive
strategy
The key studies of antithrombin therapy in NSTEMI
patients are summarised in Table 2 (4,38–48). The
ACC⁄AHA guidelines recommend the use of enoxap-
arin or unfractionated heparin (UFH) as antithrom-
bin therapy in the invasive pathway (class IA
recommendation; level of evidence: A) (1). The
ACC⁄AHA guidelines also recommend fondaparinux
during an invasive approach (class IB recommenda-
tion; level of evidence: B). The current evidence indi-
cates that fondaparinux and UFH have comparable
clinical safety in patients undergoing PCI in both
NSTEMI (12,48) and STEMI (47) patients. However,
there was a higher rate of guiding catheter thrombosis
with fondaparinux in the OASIS-5 trial (3). After the
OASIS-5 protocol was amended to include adminis-
tration of i.v. UFH to patients undergoing PCI, the
rate of this complication was lower (3). However,
the exact dose of UFH needed to prevent catheter-
thrombosis formation during the use of fondaparinux
in patients undergoing PCI remains undeﬁned. This
confusion regarding heparin dosing in the catheteri-
sation laboratory in patients already on fondaparinux
has led to slow acceptance of fondaparinux in high-
risk patients.
On the basis of ﬁndings from OASIS-5 in NSTE-
MI patients, the guidelines also recommend
upstream therapy with fondaparinux in patients
managed conservatively with a high risk of bleeding
(class IB recommendation; level of evidence: B). This
recommendation for the broader application of
fondaparinux in patients at high risk of bleeding was
made despite the lack of direct evidence for an asso-
ciation between patient characteristics and bleeding
rates from the OASIS-5 trial (3).
Hence, although the study data on fondaparinux
are generally robust, there are various details missing
from the published literature with fondaparinux and
further information is required to help guide the
‘interventionalists’ in this situation. The manufactur-
ers of fondaparinux have applied for US Food and
Drug Administration (FDA) approval for an indica-
tion for use in ACS.
Use of upstream bivalirudin
Bivalirudin is indicated as an antithrombin therapy in
patients undergoing an invasive strategy (class IB
recommendation; level of evidence: B). The use of
upstream bivalirudin is also indicated as an alternative
to GP IIb⁄IIIa inhibitors (class IIa recommendation;
level of evidence: B) (1), but only with the concomi-
tant use of clopidogrel. However, there are limited
data on upstream use of bivalirudin. The use of biva-
lirudin monotherapy, bivalirudin plus GP IIb⁄IIIa
inhibitors and heparin plus GP IIb⁄IIIa inhibitors was
investigated in the ACUITY trial (Table 2) (4). The
30-day rates of composite ischaemic end-point of
death, MI, or unplanned revascularisation for ischae-
mia were 7.7%, 7.3% and 7.8% for bivalirudin plus
GP IIb⁄IIIa inhibitors, heparin plus GP IIb⁄IIIa inhib-
itors and bivalirudin monotherapy respectively. The
RR (95% CI) for the comparison between heparin plus
GP IIb⁄IIIa inhibitors vs. bivalirudin plus GP IIb⁄IIIa
inhibitors was 1.01 (0.90–1.12) and for the compari-
son between heparin plus GP IIb⁄IIIa inhibitors and
bivalirudin alone, 1.08 (0.93–1.24). The rates of major
bleeding for the same groups were 5.3%, 5.7% and
3.0% respectively and the RRs (95% CIs) were 0.93
(0.78–1.10) and 0.53 (0.43–0.65) respectively (4).
These data suggest that bivalirudin alone could be
used to achieve similar efﬁcacy and a reduction in
major bleeding. However, the utilisation of bivalirudin
upstream in the ACUITY trial was relatively short,
with a median infusion duration of < 6 h. In addition,
the majority of patients in ACUITY had been pretreat-
ed with heparin or enoxaparin prior to randomisation.
As such, it is unclear how effective bivalirudin alone is
in prolonged upstream precatheterisation medical
management.
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excluded for high-risk patients. In particular, the use
of GP IIb⁄IIIa inhibitors should be considered for
those with positive troponin and for those not pre-
treated with thienopyridine. Bivalirudin monotherapy
in patients with positive troponin and for those not
pretreated with thienopyridine was associated with
an increased RR for ischaemic events, 1.12 (95% CI
0.94–1.34) and 1.29 (95% CI 1.03–1.63) respectively
(4,49). Currently, bivalirudin remains an unapproved
and expensive treatment option outside the catheteri-
sation laboratory, with limited data on upstream
effectiveness.
Putting it all together: matching
treatment to risk
The ACC⁄AHA guideline recommended therapies for
patients with UA⁄NSTEMI are best utilised in a risk-
matched strategy, which couples high-intensity treat-
ment with high-risk patients and lower-intensity
treatment with lower-risk patients. Matching treat-
Figure 3 Risk-stratiﬁcation treatment strategy for the management of non-ST-elevation myocardial infarction (NSTEMI)-
acute coronary syndrome (ACS) (used with permission from Cohen, et al. Strategies for optimizing outcomes in the
NSTE-ACS patient The CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus
Panel Report. J Invasive Cardiol 2006; 18: 617–39) (50)
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Journal compilation ª 2009 Blackwell Publishing Ltd Int J Clin Pract, April 2009, 63, 4, 642–655ment to risk is easily accomplished by utilising the
invasive pathway for the highest-risk patients and the
conservative pathway for lower-risk patients and
starting this differentiation as early as the emergency
department.
Thus, as mentioned above, patients with ECG ST
deviation or elevated troponins or a TIMI score > 3
should be treated upstream as per the invasive path-
way (Figure 3) (50). Invasive pathway medications
include anti-ischaemics [oxygen, nitrates, beta-block-
ers and angiotensin-converting enzyme (ACE) inhibi-
tors], aspirin, either clopidogrel or a GP inhibitor
and an antithrombin (UFH or enoxaparin). An alter-
native to heparins plus a GP inhibitor is bivalirudin
administered upstream with concomitant clopidogrel.
In higher-risk patients, with elevated troponin, recur-
rent ischaemia on therapy or delay to catheterisation,
triple antiplatelet therapy with aspirin, clopidogrel
and a GP inhibitor is an alternative strategy.
In lower-risk patients, with non-diagnostic ECGs,
normal troponins and TIMI scores of 2–3, the con-
servative or selectively invasive strategy is preferable
(Figure 3) (50). Other patients who would ﬁt in this
strategy are high-risk patients who are not eligible
for catheterisation for reasons of lack of capabilities,
patient preference and physician preference. Conser-
vative pathway treatments include anti-ischaemic
therapy, aspirin, clopidogrel and an antithrombin or
factor Xa inhibitor such as fondaparinux. LMWHs
such as enoxaparin are preferable to UFH in these
medically-managed patients. Patients in the conserva-
tive pathway are admitted to the hospital for serial
ECGs, serial troponins and provocative testing. Cath-
eterisation is reserved for those patients who develop
recurrent chest pain, ECG changes, elevated tropo-
nins, high-risk provocative testing results or a left-
ventricular ejection fraction (LVEF) < 40%. If these
complications develop, then the patient is transferred
to the invasive pathway and cardiac catheterisation is
performed.
Conclusions
Although the ACC⁄AHA guidelines are a compre-
hensive tool for the management of patients with
NSTEMI, additional factors need to be taken into
consideration to aid the decision-making process.
Rapid and accurate risk stratiﬁcation is essential to
determine whether to use an early or selectively
invasive strategy. Consideration of the risk of com-
plications during subsequent procedures, e.g. catheter
thrombosis during PCI with fondaparinux and bleed-
ing with clopidogrel during CABG, are also impor-
tant determinants for the choice of treatment.
Finally, upstream medical management should be
matched with catheter-based therapies to ensure
seamless transitions from the precatheterisation med-
ical management phase of therapy to the catheterisa-
tion laboratory. Although the new ACC⁄AHA
guidelines provide many options for both precathete-
risation medical management as well as catheter-
based therapy, they do not provide the guidance
needed to facilitate transition of care in a way that
matches treatment to risk. Protocol development
within an institution is required to risk-stratify
patients rapidly, provide optimum precatheterisation
medical management and allow seamless and rapid
transitions to the catheterisation laboratory in
patients at risk for adverse events.
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